Hypertension, proteinuria, and AAS are the most severe adverse effects of anti-VEGF drugs.3,9 However, no pharmacovigilance study exists to explore the relationship between VEGF inhibitor–mediated AAD with ICB and the knowledge of vascular safety profile. The gene discussed is VEGFA; the disease is hypertensive disorder.